The previous post, regarding the DEA’s suspension of McKesson Corporation’s sales of controlled substances from distribution in Florida, was found to be confusing. This suspension will impact one distribution center in Florida and impacts only the handling of hydromorphone. The Florida Department of Health and Division of Medical Quality Assurance apologizes for any confusion that may have resulted from that message. For specific details about McKesson’s agreement with the DEA, please contact the DEA. For questions about the potential impact of the sanctions in Florida, please contact the DOH’s Medical Quality Assurance.
More Latest News
March 2, 2017
The boards of pharmacy will elect officers and members of the NABP Executive Committee, review and vote on NABP policies, and guide the direction of the Association Continue reading
February 17, 2017
Effective January 12, 2017 Florida Administrative Code, 64K-1.004 Management and Operation of Database has been amended requiring all pharmacies that DO NOT dispense controlled substances in or into this state submit a Notification of Exemption from Reporting (Form DH8016-PDMP). Exemptions … Continue reading